A new research review published by Cambridge University Press evaluated 292 random control trials (RCTs) studying Attention Deficit Hyperactive Disorder (ADHD) in adults and found that half of the studies do not use a clear diagnostic criterion to ensure participants have the condition.

“Our finding that half of the RCTs exhibited little or no interest in securing the validity of the ADHD diagnosis and that it was unclear who made the diagnosis in 2/3 of the studies is certainly alarming,” the authors wrote. “The diagnostic assessment is the foundation, which all subsequent analyses are built upon. As long as it remains unclear precisely what disorder is being examined in scientific studies, the findings of these studies will have limited value.”

The authors explained that the ADHD diagnostic criteria for adults are challenging for several reasons. ADHD originally began as a disorder to describe children, which was called Hyperkinetic Reaction of Childhood (or Adolescence) in 1968. The condition is described as “overactivity, restlessness, distractibility, and short attention span, especially in young children; the behavior usually diminishes in adolescence.”

The authors note that parents and teachers were responsible for observing this behavior in children and reporting the behavior to health professionals. That was the foundation of a clinical diagnosis in the DSM-II. “In the subsequent versions of the DSM, the diagnostic criteria for ADHD have been diluted and become more inclusive,” the study authors wrote.

The diagnostic criteria was intended for use in children based on observations made by parents and teachers. Diagnosis for adults relies solely on self-reports made by the individual, including retrospective recall of childhood symptoms, which the authors say is “notoriously poor.” The DSM 5 diagnostic criteria were not tested on adults before publication.

A systematic review from 2023 referenced by the authors found that most clinical samples found that less than 20% of those testing positive for ADHD were actually false positives. This is based on self-reporting diagnostic criteria. The authors of the 2023 review said the highest rate was 61%, meaning 39% of those who test positive actually do not have ADHD.

Dr. Richard Saul authored the book “ADHD Does Not Exist: The Truth About Attention Deficit and Hyperactivity Disorder,” and also wrote an op-ed for Time Magazine in 2014. Dr. Saul explained that only five out of 18 behaviors, which most people can relate to, include poor organization skills, a tendency to lose things, or failing to pay attention to details.

Dr. Saul said he has identified over 20 conditions that lead to the same symptoms of ADHD and that each one of these conditions requires a different approach for treatment. Some of these conditions include sleep disorders, vision and hearing problems, substance abuse, iron deficiency, allergies, bipolar disorder, and obsessive compulsive disorder among others. Dr. Saul stressed that stimulants are not an appropriate medication for people who are suffering from these particular conditions, which could be misdiagnosed as ADHD.

According to the CDC, 6% of U.S. adults are diagnosed with ADHD based on self-reports, which equates to 15.5 million. About one-third of adults diagnosed with the condition have taken stimulants within the last year to treat the condition.

Margaret Sibleyis, a professor of psychiatry and behavior sciences, published an article this week for AEON stating that adult ADHD “is becoming more inclusive” and “that’s not the same as being overdiagnosed.” Sibleyis wrote that an ADHD diagnosis is the extreme end of a continuum in which the average adult experiences two to three symptoms and can cross the clinical threshold during particularly stressful periods.

Sibleyis describes a clinical edge case by the name of Rebecca, who at the age of 40 clicked on Facebook ads that suggested she may have ADHD. The ads read, “Working hard but not moving up? You might have undiagnosed ADHD,” and “Indecisive? Anxious? A two-minute quiz can tell you if you have ADHD.”

Sibleyis said Rebecca has had a “moderate amount of relationship and employment instability,” which “can be linked to a pattern of restlessness.” With only three symptoms of inattention and two of hyperactivity, the clinician could make the determination based on an interview with Rebecca’s boyfriend, who describes behaviors of forgetfulness, distractibility, and talkativeness.

The clinician would make the determination based on whether Rebecca’s symptoms are interfering with her ability to function. Different clinicians could easily come up with different determinations for Rebecca.

Diagnoses of children with ADHD and subsequent medication prescriptions are also questioned as rates continue to rise. In addition, the proliferation of technology like smartphones and tablets has significantly increased the amount of screen time. 40% of children consistently use a tablet by the age of two, and children under eight have increased gaming time by 65% over the last four years.

A 2024 study found 10.5% of children had a current ADHD diagnosis, and 53.6% of those with a diagnosis received medication, which equates to more than four million children in the United States. 77.9% had at least one co-occurring disorder, including depression and anxiety, which the authors said can be hard to distinguish from ADHD.

The FDA announced this week that extended-release stimulants, like ritalin, that are prescribed for ADHD will have a weight loss warning for children under 6. These products are only approved for children over the age of 6, but it can and is prescribed off-label for young children. The CDC website states that medication should only be given to children under 6 after behavioral therapy has been tried because stimulant medication is less effective and has more side effects for this age group.

The 2016 National Survey of Children’s Health (NSCH) found 62% of children aged 2-7 were taking medication, and 46.7% received some behavioral treatment within the last year. The 2022 survey found 18% of children aged 2-5 diagnosed with ADHD received medication, and 69% of children aged 6-11.

Steven Middendorp

Steven Middendorp is an investigative journalist, musician, and teacher. He has been a freelance writer and journalist for over 20 years. More recently, he has focused on issues dealing with corruption and negligence in the judicial system. He is a homesteading hobby farmer who encourages people to grow their own food, eat locally, and care for the land that provides sustenance to the community.

Other Headlines

Coronavirus

ICAN Releases Recordings of FDA’s Peter Marks; Vaccine Official Dismissed Vaccine Injuries

The Informed Consent Action Network (ICAN) and REACT 19 held a joint press conference today to reveal a trove of secret recordings and FOIA documents of Peter Marks, the former Director of the Center for Biologics Evaluation and Research. The press conference included ICAN Founder Del Bigtree, Attorney Aaron Siri, and REACT 19’s Brianne Dressen.Continue reading ICAN Releases Recordings of FDA’s Peter Marks; Vaccine Official Dismissed Vaccine Injuries

More news about Coronavirus

Health & Nutrition

Ozempic and GLP-1 Drugs Linked to Insurance Hikes, Pancreatitis Risk

Ozempic and GLP-1 agonists are causing skyrocketing rates of health insurance premiums as serious side effects from the drug have sparked a new UK investigation. GLP-1 agonists, including Ozempic and Wegovy, are used for weight loss and to treat diabetes, but can cost between $1,000 and $1,500 per month for a prescription without insurance. TheContinue reading Ozempic and GLP-1 Drugs Linked to Insurance Hikes, Pancreatitis Risk

More news about Health & Nutrition

Vaccines

Moderna’s SpikeVax Gets Full FDA Approval for High-Risk Children Amid Lawsuit Over Vaccine Policy Shift

Moderna received full FDA approval for its COVID-19 mRNA vaccine, called SpikeVax, for use in children aged 6 months to 11 years who are considered high risk. Previously, this vaccine was only given an Emergency Use Authorization (EUA) for this age group. In May, the CDC announced a change in its COVID-19 vaccine policy, noContinue reading Moderna’s SpikeVax Gets Full FDA Approval for High-Risk Children Amid Lawsuit Over Vaccine Policy Shift

More news about Vaccines

Science & Tech

Coinbase CEO Brian Armstrong Eyes Embryo-Editing Startup

Coinbase CEO Brian Armstrong declared his interest in creating a startup to work on gene-editing embryos, a type of editing that people say will lead to the creation of “designer babies.” CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has been used in the medical field to help with certain conditions, and recently, a babyContinue reading Coinbase CEO Brian Armstrong Eyes Embryo-Editing Startup

More news about Science & Tech

Environment

USDA to Build Sterile Fly Factory to Stop Flesh-Eating Maggots from Invading U.S.

The USDA is going to breed millions of flies, sterilize them with radiation, and send them into Texas and Mexico to prevent a re-emergence of the New World Screwworm(NWS), also known as a flesh-eating maggot. The NWS is endemic to Cuba, the Dominican Republic, and some South American countries, but it was eradicated in theContinue reading USDA to Build Sterile Fly Factory to Stop Flesh-Eating Maggots from Invading U.S.

More news about Environment

Policy

Moderna’s SpikeVax Gets Full FDA Approval for High-Risk Children Amid Lawsuit Over Vaccine Policy Shift

Moderna received full FDA approval for its COVID-19 mRNA vaccine, called SpikeVax, for use in children aged 6 months to 11 years who are considered high risk. Previously, this vaccine was only given an Emergency Use Authorization (EUA) for this age group. In May, the CDC announced a change in its COVID-19 vaccine policy, noContinue reading Moderna’s SpikeVax Gets Full FDA Approval for High-Risk Children Amid Lawsuit Over Vaccine Policy Shift

More news about Policy